On Wednesday, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s shares gained 4.05%, and closed at $34.17, after a biopharmaceutical corporation, declared that it will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015, at 9:20 a.m. Eastern Time in New York City.
A live webcast of ACADIA’s presentation will be accessible on the corporation’s website, www.acadia-pharm.com, under the investors section and an archived recording will be accessible on the website through April 28, 2015.
ACADIA Pharmaceuticals Inc., a biopharmaceutical corporation, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
HomeAway, Inc. (NASDAQ:AWAY)’s shares jumped 3.98%, and settled at $31.90, during the last trading session on Wednesday, after the world’s leading online marketplace for the vacation rental industry, declared recently it will report its financial results for the first quarter ended March 31, 2015 on Thursday, April 23, 2015 after the close of market. HomeAway(R) will host a conference call to review and talk about the first quarter results at 4:30 p.m. Eastern Time / 3:30 p.m. Central Time. In addition, a live webcast of the call will be accessible through the Investor Relations section of HomeAway’s website and will be archived online for 60 days upon completion of the conference call.
HomeAway, Inc., together with its auxiliaries, operates an online vacation rental property marketplace that enables property owners and managers to market properties for rental to vacation travelers. The corporation’s portfolio comprises vacation rental Websites, such as HomeAway.com, VRBO.com, and VacationRentals.com in the United States; HomeAway.co.uk and OwnersDirect.co.uk in the United Kingdom; HomeAway.de in Germany; Abritel.fr and Homelidays.com in France; HomeAway.es and Toprural.com in Spain; AlugueTemporada.com.br in Brazil; HomeAway.com.au and Stayz.com.au in Australia; and Bookabach.co.nz in New Zealand.
At the end of Wednesday’s trade, Delta Air Lines, Inc. (NYSE:DAL)’s shares climbed 3.96%, and closed at $43.29, as Delta Air Lines will hold a live conference call and webcast to talk about its March quarter 2015 financial results at 10 a.m. ET, April 15, 2015.
Delta Air Lines, Inc. provides planned air transportation for passengers and cargo worldwide. The corporation operates in two segments, Airline and Refinery. Its route network comprises various gateway airports in Amsterdam, Detroit, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita.
Nektar Therapeutics (NASDAQ:NKTR), ended its Wednesday’s trading session with 3.91% gain, and closed at $11.15, as on April 2, a biopharmaceutical corporation, declared that it has received a $100 million payment under a license contract with AstraZeneca. The cash payment under the Nektar-AstraZeneca contract was triggered by the first commercial sale of MOVANTIK (naloxegol) in the U.S. MOVANTIK is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.
MOVANTIK was developed using Nektar’s oral small molecule polymer conjugate technology. MOVANTIK is part of the exclusive worldwide license contract declared on September 21, 2009 between AstraZeneca and Nektar Therapeutics. Under the terms of the contract, in addition to the $100 million milestone payment declared recently, Nektar is entitled to a $40 million milestone payment upon first commercial sale of MOVANTIK in a major European country, in addition to royalties on worldwide net product sales and up to $375 million in sales milestones. The royalty rate in the U.S. starts at 20% and escalates. The royalty rate in Europe and the rest of the world starts at 18% and escalates. Under the contract, AstraZeneca is responsible for all sales and marketing activities for MOVANTIK worldwide.
Nektar Therapeutics, a biopharmaceutical corporation, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
